A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities.
Mechanism of action
Pembrolizumab is a humanized monoclonal IgG4 kappa antibody directed against human cell surface PD-1 (programmed death receptor-1) on lymphocytes. The PD-1 receptor provides a critical “immune checkpoint,” which helps prevent the immune system from attacking itself. Certain tumors have a high expression of PD-L1(programmed death receptor ligand-1). Other tumor types use adaptive immune resistance, which takes the natural physiology of PD-L1 induction (protection of immune-mediated damage from infections) and adapts it to anti-tumor responses. When PD-L1 engages with PD-1, the T-cell function becomes inhibited; pembrolizumab blocks the PD-1: PDL-1 complex formation, allowing improved T-cell mediated killing[1-2].
Pembrolizumab Upstream-Materialien And Downstream Produkte
PembrolizumabQ: What is
Pembrolizumab Q: What is the CAS Number of
Pembrolizumab Q: What is the storage condition of
Pembrolizumab Q: What are the applications of
Pembrolizumab
Research Grade Pembrolizumab(DHH02202)
MK-3475
Research Grade Pembrolizumab
Pembrolizumab - in storage buffer (ca 25 mg/ml)
1374853-91-4
Copyright 2019 ? ChemicalBook. All rights reserved
Product Name*
CAS.No
Inquiry Amount*
Port*
Inquiry Description*
+Add Attachment(File Format: Jpg, Gif, Png, PDF,Zip,Txt,doc or xls Max Size: 3MB)